Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

KW-6002 (Kyowa Hakko Kogyo).

L J Knutsen¹, S M Weiss

¹Vernalis Research Limited, Wokingham, Berkshire, UK. L.Knutsen@vernalis.com

Current Opinion in Investigational Drugs (London, England : 2000)

|September 25, 2001

Summary

Kyowa Hakko is developing KW-6002, an adenosine A2A receptor antagonist, for Parkinson's disease and depression. This novel drug shows promise as a new class of antidepressants and may avoid movement side effects associated with L-DOPA.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Photonic metacrystal: design methodology and experimental characterization.

Optics express·2022

Same author

The association of HIV and cocaine use to cigarette smoking in the context of depression and perceived stress.

AIDS care·2020

Same author

Stigma interdependence among pregnant HIV-infected couples in a cluster randomized controlled trial from rural South Africa.

Social science & medicine (1982)·2020

Same author

A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa.

AIDS and behavior·2018

Same author

Translating evidence-based interventions from research to practice: challenges and lessons learned.

Translational behavioral medicine·2015

Same author

Reducing the risk of HIV infection during pregnancy among South African women: a randomized controlled trial.

AIDS care·2013

Area of Science:

Pharmacology
Neuroscience
Drug Development

Background:

Kyowa Hakko is developing KW-6002, a selective adenosine A2A receptor antagonist.
KW-6002 is being investigated for the treatment of Parkinson's disease (PD) and depression.

Purpose of the Study:

To evaluate KW-6002 as a potential treatment for Parkinson's disease.
To assess KW-6002's efficacy and safety as an antidepressant.

Main Methods:

Phase II clinical trials for Parkinson's disease in Japan, Europe, and the US.
Preclinical studies in a depression model.
Phase II trial for depression initiated in June 2000.

Main Results:

Positive results observed in a preclinical depression model.
KW-6002 is undergoing Phase II trials for PD and depression.
The drug is noted for potentially lacking the involuntary movement side effects of L-DOPA therapy.

Conclusions:

KW-6002 represents a potential new class of antidepressants.
The drug is of significant interest for Parkinson's disease treatment due to its distinct side effect profile.
Regulatory filings (NDAs) are anticipated around late 2001 for Western Europe launch in 2002.

Related Experiment Videos